First Patient Enrolled in Phase 1/2 Trial for Recurrent Ovarian Cancer
News
The first patient has been dosed in a Phase 1/2 trial assessing OncoQuest‘s anti-CA125 antibody oregovomab in combination with Opdivo (nivolumab) in women with recurrent ovarian cancer. The ORION-01 trial (NCT03100006), ... Read more